NASDAQ: CGEM
Cullinan Therapeutics Inc Stock Ownership - Who owns Cullinan Therapeutics?

Insider buying vs selling

Have Cullinan Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Lynx1 Capital Management LP10% Owner2025-10-1732,217$7.84
$252.58kBuy
Lynx1 Capital Management LP10% Owner2025-10-16150,000$8.86
$1.33MBuy
Lynx1 Capital Management LP10% Owner2025-10-1551,500$7.94
$409.06kBuy
Lynx1 Capital Management LP10% Owner2025-10-1415,032$7.59
$114.05kBuy
Lynx1 Capital Management LP10% Owner2025-10-10277,298$7.36
$2.04MBuy
Lynx1 Capital Management LP10% Owner2025-10-09626,043$6.70
$4.19MBuy
Lynx1 Capital Management LP10% Owner2025-10-08556,300$6.46
$3.59MBuy
Jacquelyn L. SumerChief Legal Officer2025-02-253,756$8.53
$32.04kSell
Nadim AhmedPresident and CEO2025-02-2512,529$8.53
$106.87kSell
Jeffrey Alan JonesChief Medical Officer2025-02-254,895$8.53
$41.75kSell

1 of 2

CGEM insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CGEM insiders and whales buy or sell their stock.

CGEM Shareholders

What type of owners hold Cullinan Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ansbert Gadicke27.38%16,157,644$125.38MInsider
Lynx1 Capital Management LP14.91%8,797,833$68.27MInsider
Ubs Oncology Impact Fund LP12.96%7,648,268$59.35MInsider
Mpm Bioimpact LLC12.96%7,648,268$59.35MInstitution
Bvf Inc9.74%5,750,683$44.63MInstitution
Morana Jovanembiricos7.85%4,631,022$35.94MInsider
Vision Scs F27.59%4,476,350$34.74MInsider
F2 Bioscience I 2017 Ltd7.51%4,430,964$34.38MInsider
Lynx1 Capital Management LP7.46%4,400,842$34.15MInstitution
Blackrock Inc7.15%4,217,933$32.73MInstitution

1 of 3

CGEM vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CGEM56.20%43.80%Net BuyingNet Buying
ADCT60.40%38.28%Net Buying
QSI31.75%50.61%Net SellingNet Selling
ALMS75.27%24.28%Net Buying
OCGN17.67%10.44%Net Selling

Cullinan Therapeutics Stock Ownership FAQ

Who owns Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ: CGEM) is owned by 106.09% institutional shareholders, 82.67% Cullinan Therapeutics insiders, and 0.00% retail investors. Ansbert Gadicke is the largest individual Cullinan Therapeutics shareholder, owning 16.16M shares representing 27.38% of the company. Ansbert Gadicke's Cullinan Therapeutics shares are currently valued at $125.38M.

If you're new to stock investing, here's how to buy Cullinan Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.